{"id":55294,"date":"2026-01-23T14:57:27","date_gmt":"2026-01-23T06:57:27","guid":{"rendered":"https:\/\/flcube.com\/?p=55294"},"modified":"2026-01-23T14:57:28","modified_gmt":"2026-01-23T06:57:28","slug":"sisram-medical-partners-with-fosun-pharma-subsidiary-on-local-production-base","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55294","title":{"rendered":"Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base"},"content":{"rendered":"\n<p><strong>Sisram Medical Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1696:HKG\">HKG: 1696<\/a>), an Israel\u2011based beauty and wellness group and part of <strong>Fosun Pharmaceutical Group<\/strong>, announced the signing of a <strong>Letter of Intent (LOI)<\/strong> with <strong>Sinmait Medical Technology (Beijing) Co., Ltd.<\/strong>, a Fosun Pharma subsidiary, to jointly establish a <strong>local production base<\/strong> in China. The collaboration aims to shorten the product supply chain, optimize cost structure, and enhance operational efficiency and market response flexibility.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-structure-amp-strategic-terms\">Partnership Structure &amp; Strategic Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Sisram Medical Ltd (01696.HK)<\/td><\/tr><tr><td><strong>Partner<\/strong><\/td><td>Sinmait Medical Technology (Beijing) Co., Ltd.<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>Letter of Intent (LOI)<\/td><\/tr><tr><td><strong>Purpose<\/strong><\/td><td>Jointly establish local production base<\/td><\/tr><tr><td><strong>Parent Group<\/strong><\/td><td>Fosun Pharmaceutical Group<\/td><\/tr><tr><td><strong>Scope<\/strong><\/td><td>Complete localized industrial ecosystem for beauty and wellness devices<\/td><\/tr><tr><td><strong>Key Products<\/strong><\/td><td>Energy-based devices and injectable filler products<\/td><\/tr><tr><td><strong>Strategic Benefits<\/strong><\/td><td>Supply chain optimization, cost reduction, operational efficiency<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-market-position\">Strategic Context &amp; Market Position<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sisram&#8217;s Business:<\/strong> Global beauty and wellness group dedicated to building a customer-oriented ecosystem centered on <strong>energy-based devices and injectable filler products<\/strong><\/li>\n\n\n\n<li><strong>Market Need:<\/strong> China represents the <strong>fastest-growing<\/strong> market for aesthetic medical devices, demanding localized production to meet regulatory requirements and cost pressures<\/li>\n\n\n\n<li><strong>Fosun Synergy:<\/strong> Leverages Fosun Pharma&#8217;s domestic manufacturing expertise and Sinmait&#8217;s local market knowledge<\/li>\n\n\n\n<li><strong>Industrial Ecosystem:<\/strong> Collaboration will establish a <strong>complete, resilient, and competitive localized industrial ecosystem<\/strong> from R&amp;D to commercialization<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Aesthetics Market:<\/strong> Valued at <strong>\u00a550 billion<\/strong> (~US$7 billion) in 2025, growing at <strong>15% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Cost Advantage:<\/strong> Local production expected to reduce manufacturing costs by <strong>20-30%<\/strong> and improve gross margins<\/li>\n\n\n\n<li><strong>Supply Chain:<\/strong> Shortened lead times from <strong>12 weeks to 4 weeks<\/strong>, enabling faster market response<\/li>\n\n\n\n<li><strong>Revenue Impact:<\/strong> Analysts project <strong>\u00a5800 million &#8211; 1.2 billion<\/strong> in additional annual revenue from China market by 2028<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong>: Local production facilitates faster NMPA approvals and reimbursement listing<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Definitive agreement expected Q2 2026, with production base operational by 2027<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the partnership&#8217;s operational timeline, cost savings, and revenue projections. Actual results may differ due to regulatory approvals, market conditions, and execution risks.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sisram Medical Ltd (HKG: 1696), an Israel\u2011based beauty and wellness group and part of Fosun&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[159,1180,100,4574,357],"class_list":["post-55294","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-fosun-pharmaceutical","tag-hkg-1696","tag-medical-aesthetics","tag-sinmait-medical-technology","tag-sisram-medical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sisram Medical Ltd (HKG: 1696), an Israel\u2011based beauty and wellness group and part of Fosun Pharmaceutical Group, announced the signing of a Letter of Intent (LOI) with Sinmait Medical Technology (Beijing) Co., Ltd., a Fosun Pharma subsidiary, to jointly establish a local production base in China. The collaboration aims to shorten the product supply chain, optimize cost structure, and enhance operational efficiency and market response flexibility.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55294\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base\" \/>\n<meta property=\"og:description\" content=\"Sisram Medical Ltd (HKG: 1696), an Israel\u2011based beauty and wellness group and part of Fosun Pharmaceutical Group, announced the signing of a Letter of Intent (LOI) with Sinmait Medical Technology (Beijing) Co., Ltd., a Fosun Pharma subsidiary, to jointly establish a local production base in China. The collaboration aims to shorten the product supply chain, optimize cost structure, and enhance operational efficiency and market response flexibility.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55294\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-23T06:57:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-23T06:57:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55294#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55294\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base\",\"datePublished\":\"2026-01-23T06:57:27+00:00\",\"dateModified\":\"2026-01-23T06:57:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55294\"},\"wordCount\":341,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Fosun Pharmaceutical\",\"HKG: 1696\",\"Medical aesthetics\",\"Sinmait Medical Technology\",\"Sisram Medical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55294#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55294\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55294\",\"name\":\"Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-23T06:57:27+00:00\",\"dateModified\":\"2026-01-23T06:57:28+00:00\",\"description\":\"Sisram Medical Ltd (HKG: 1696), an Israel\u2011based beauty and wellness group and part of Fosun Pharmaceutical Group, announced the signing of a Letter of Intent (LOI) with Sinmait Medical Technology (Beijing) Co., Ltd., a Fosun Pharma subsidiary, to jointly establish a local production base in China. The collaboration aims to shorten the product supply chain, optimize cost structure, and enhance operational efficiency and market response flexibility.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55294#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55294\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55294#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base - Insight, China&#039;s Pharmaceutical Industry","description":"Sisram Medical Ltd (HKG: 1696), an Israel\u2011based beauty and wellness group and part of Fosun Pharmaceutical Group, announced the signing of a Letter of Intent (LOI) with Sinmait Medical Technology (Beijing) Co., Ltd., a Fosun Pharma subsidiary, to jointly establish a local production base in China. The collaboration aims to shorten the product supply chain, optimize cost structure, and enhance operational efficiency and market response flexibility.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55294","og_locale":"en_US","og_type":"article","og_title":"Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base","og_description":"Sisram Medical Ltd (HKG: 1696), an Israel\u2011based beauty and wellness group and part of Fosun Pharmaceutical Group, announced the signing of a Letter of Intent (LOI) with Sinmait Medical Technology (Beijing) Co., Ltd., a Fosun Pharma subsidiary, to jointly establish a local production base in China. The collaboration aims to shorten the product supply chain, optimize cost structure, and enhance operational efficiency and market response flexibility.","og_url":"https:\/\/flcube.com\/?p=55294","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-23T06:57:27+00:00","article_modified_time":"2026-01-23T06:57:28+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55294#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55294"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base","datePublished":"2026-01-23T06:57:27+00:00","dateModified":"2026-01-23T06:57:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55294"},"wordCount":341,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Fosun Pharmaceutical","HKG: 1696","Medical aesthetics","Sinmait Medical Technology","Sisram Medical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55294#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55294","url":"https:\/\/flcube.com\/?p=55294","name":"Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-23T06:57:27+00:00","dateModified":"2026-01-23T06:57:28+00:00","description":"Sisram Medical Ltd (HKG: 1696), an Israel\u2011based beauty and wellness group and part of Fosun Pharmaceutical Group, announced the signing of a Letter of Intent (LOI) with Sinmait Medical Technology (Beijing) Co., Ltd., a Fosun Pharma subsidiary, to jointly establish a local production base in China. The collaboration aims to shorten the product supply chain, optimize cost structure, and enhance operational efficiency and market response flexibility.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55294#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55294"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55294#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55294"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55294\/revisions"}],"predecessor-version":[{"id":55295,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55294\/revisions\/55295"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}